Cheng Huang

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Yi‐Long Wu, Caicun Zhou, Chong Kin Liam et al. · Annals of Oncology · 2015 · 726 citations

Medicine, Phase Iii, Pathology +7

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 520 citations

Medicine, Pathology, Gefitinib Versus Vinorelbine +8

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · Journal of Clinical Oncology · 2020 · 261 citations · Full text

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Baohui Han, Kai Li, Yizhuo Zhao et al. · British Journal of Cancer · 2018 · 260 citations · Full text

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

Yi‐Long Wu, Caicun Zhou, Ying Cheng et al. · Annals of Oncology · 2012 · 236 citations · Full text

Second-line Treatment, Medicine, Pathology +7